Home Nav
Nextech Invest Logo

Kai Wucherpfennig

Alfred Scheidegger

Kai Wucherpfennig MD PhD is Professor and Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School. His research focuses on the discovery of genes that control the activity of cytotoxic T cells in the tumor microenvironment drawing insights for the development of next-generation cancer immunotherapies. He has received a number of honors and awards, including his election as a Fellow in the American Society for the Advancement of Science, his election as a member of the Henry Kunkel Society at Rockefeller University, and his election as a member of the American Society for Clinical Investigation. Dr Wucherpfennig serves as an advisor to a number of immuno-oncology companies and since 2015 is an exclusive scientific board member of Nextech Invest.

 

Personalized Oncology 2019 conference

23.06. – 25.06.2019

Basel, Switzerland

  • 24.07.2019

    Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives...

  • 18.07.2019

    Blueprint Medicines Announces European Medicines Agency...

  • 15.07.2019

    Neon Therapeutics ’ Personal Neoantigen Vaccine Study...

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close